Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC) (NEOMEL)

Centre Hospitalier Universitaire de Besancon

Status: Enrolling

Conditions: Melanoma Metastatic

Study type: Observational

Funder types: Other

Identifiers

NCT06586593

2023/758

Details and patient eligibility

About

This study aims to evaluate efficacy and tolerance of real life neoadjuvant immunotherapy in advanced yet operable melanoma.

The complete histological response will be assessed.

Enrollment: 77 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with operable metastatic melanoma (stage III or IV of American Joint Committee on Cancer [AJCC] Stages CLassification) treated with neoadjuvant immunotherapy (anti-PD1 or anti-PD1 + anti-CTLA-4), even if surgery cancelled due to disease progression or complete response or patient's refusal to be operated.
• Efficacy of the neoadjuvant immunotherapy histologically of radiologically assessed

Exclusion criteria

• Uveal melanoma

Trial design

77 participants in 1 patient group

Operable metastatic melanoma

Description:

Operable metastatic melanoma